July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
A Novel Contrast Sensitivity Test as a Measure of Functional Vision in Macular Telangiectasia and Central Retinal Vein Occlusion
Author Affiliations & Notes
  • Rebecca F Silverman
    Retina Service, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Ines Lains
    Retina Service, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Department of Ophthalmology, University of Coimbra, Coimbra, Portugal
  • Ava K Bittner
    Nova Southeastern University, College of Optometry, Fort Lauderdale, Florida, United States
  • Luis A Lesmes
    Adaptive Sensory Technology, Inc. , San Diego, California, United States
  • John B Miller
    Retina Service, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Rebecca Silverman, None; Ines Lains, Allergan (C); Ava Bittner, Adaptive Sensory Technology (F); Luis Lesmes, Adaptive Sensory Technology (I), Adaptive Sensory Technology (E), Adaptive Sensory Technology (P); John Miller, Allergan (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 786. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rebecca F Silverman, Ines Lains, Ava K Bittner, Luis A Lesmes, John B Miller; A Novel Contrast Sensitivity Test as a Measure of Functional Vision in Macular Telangiectasia and Central Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2018;59(9):786.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Traditional letter visual acuity does not always adequately describe a patient’s visual limitations or pathologic changes in a variety of maculopathies. Herein, we evaluate the utility of a computerized contrast testing device in patients with macular telangiectasia (mac tel) and central retinal vein occlusion (CRVO).

Methods : Prospective, observational, IRB-approved study. All patients had a history of mac tel or CRVO in one or both eyes. Exclusion criteria was cataract status >2+ nuclear sclerosis, or visual acuity (VA) <20/200. All patients underwent quick contrast sensitivity function (qCSF) testing in each eye using the Sentio Platform (Adaptive Sensory Technologies, San Diego, CA) and SD-OCT at their regularly scheduled visit. The qCSF method uses computerized, Bayesian, adaptive testing to track changes in a patient’s contrast sensitivity with varying spatial frequencies to calculate an area under the curve (AUC). Contrast sensitivity was compared to previously collected data for 81 age-matched healthy controls, represented by calculating a Z-score (AUC-AgeMean)/AgeStdDev.

Results : 6 patients with mac tel (11 eyes) and 7 patients with CRVO (8 eyes) were tested with a mean age of 64.5 years ± 15.0. In mac tel, the mean BCVA was logMAR 0.197±0.18 (20/33) with a mean area under the CSF curve (AULCSF) of 0.609±0.20. In CRVO, the mean BCVA was logMAR 0.207±0.16 (20/32) with a mean AULCSF of 0.716±0.31. Compared to the healthy controls, we found a statistically significant reduction in mean AULCSF for both mac tel (p=9.63x10-9) and CRVO (p=0.00004). This reduction in contrast function can be further illustrated by Z-scores, demonstrating a nearly 2 standard deviation difference; Z=-1.97±0.6 in mac tel and Z=-1.91±0.9 in CRVO. Even when looking at all patients with greater than 20/30 letter acuity, the difference in AULCSF reached statistical significance (AULCSF=0.857±0.18, p=0.002).

Conclusions : We present a novel contrast test that demonstrated a statistically significant difference in contrast sensitivity function in patients with CRVO and mac tel. Further analysis of high letter acuity patients still revealed a statistically significant reduction in contrast function. CSF assessment may provide another useful clinical endpoint in disease monitoring of patients with CRVO with macular edema and macular telangiectasia.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×